Company news
Telix Pharmaceuticals Limited (ASX:TLX) news
Telix Pharmaceuticals Limited news releases on 6ix. Latest, Apr 5, 2024: Telix General Meeting Presentation
Press releases — page 4
Telix General Meeting Presentation
April 4, 2024
Telix General Meeting Chairman and CEO Addresses
April 4, 2024
Telix to Acquire ARTMS (Isotope Production Platform)
March 4, 2024
Presentation to Accompany ARTMS Acquisition
March 4, 2024
Telix to Acquire IsoTherapeutics (US R&D and Manufacturing)
February 26, 2024
2023 Full Year Results Presentation
February 22, 2024
Appendix 4E and 2023 Annual Report
February 22, 2024
2023 Full Year Results Release
February 22, 2024
Telix Acquires QSAM and its Bone Cancer Targeting Platform
February 7, 2024
Presentation to Accompany QSAM Acquisition
February 7, 2024
JP Morgan Healthcare Conference Presentation
January 8, 2024
JP Morgan Healthcare Conference and Trading Update
January 8, 2024
Telix Plans U.S. Registered Public Offering and Listing
January 4, 2024
Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
December 18, 2023
Telix Announces Proposed Acquisition of QSAM Biosciences
November 13, 2023
First Patient Dosed in Ph III ProstACT GLOBAL Therapy Study
November 12, 2023
Telix Completes Acquisition of Lightpoint Medical
November 1, 2023
ProstACT SELECT Study of TLX591 Positive Interim Readout
October 18, 2023
Q3 2023 Business Update to Accompany Quarterly Results
October 18, 2023
Activities Report and Appendix 4C - September 2023 Quarter
October 18, 2023
1H 2023 Results Release
August 23, 2023
1H 2023 Results Presentation
August 23, 2023
1H 2023 Appendix 4D and Interim Report
August 23, 2023
First Patient Dosed in Phase 3 Illuccix China Study
August 10, 2023
Q2 2023 Business Update to Accompany Quarterly Results
July 19, 2023
Activities Report and Appendix 4C - June 2023 Quarter
July 19, 2023
Lightpoint Acquisition to Expand Telix Urologic Pipeline
June 21, 2023
Phase II study for indication expansion of TLX250-CDx doses
June 18, 2023
Annual General Meeting - Presentation
May 24, 2023
Annual General Meeting - Chairman and CEO Addresses
May 23, 2023
ZIRCON Data Presented at AUA Confirms Efficacy in 2cm Masses
April 30, 2023
Presentation to Accompany AI Development Program Update
April 26, 2023
Q1 2023 Business update to accompany quarterly results
April 17, 2023
Telix Preclinical Development of Radiolabelled Olaratumab
April 16, 2023
Illuccix European Marketing Authorisation Application Update
April 2, 2023
FDA approval of expanded indication of Illuccix in the US
March 15, 2023
2022 Full Year Results Presentation
February 27, 2023
Telix Full Year Results and Investor Conference Call Details
February 20, 2023
Q4 2022 Business update to accompany quarterly results
January 17, 2023
Webcast link correction - JP Morgan Conference Presentation
January 10, 2023
ZIRCON Ph III Renal Cancer Study to be Presented at ASCO GU
December 21, 2022
Telix Acquires Optimal Tracers
November 13, 2022
ZIRCON Ph III Imaging Study - Top-Line data presentation
November 6, 2022
Q3 2022 Business Update to accompany quarterly results
October 19, 2022
TLX250-CDx Indication Expansion - Preliminary Data
October 17, 2022
Expansion of partnership with GE Healthcare in PET imaging
October 16, 2022
Health Canada Approves Illuccix for Prostate Cancer Imaging
October 13, 2022
Chinese NMPA Approves TLX250 Phase III registration study
September 27, 2022
Final IPAX-1 Study Data Confirms Safety Tolerability Profile
September 20, 2022
1H 2022 - Results Presentation
August 17, 2022